Enoxaparin in patients with primary percutaneous coronary intervention for acute ST segment elevation myocardial infarction.
The inhibition of thrombin plays a key role as adjunct therapy in the management of patients with primary percutaneous coronary intervention for ST elevation myocardial infarction. Enoxaparin provides a more predictable and constant level of anticoagulation compared with the current standard unfractionated heparin. The available data from smaller studies and prospective registries suggest that enoxaparin is associated with a reduction in the rate of death and nonfatal reinfarction after primary percutaneous coronary intervention without an increase in bleeding complications. Thus, a large randomized trial is warranted to further evaluate the role of enoxaparin in these patients.
Herzzentrum Ludwigshafen, Medizinische Klinik B, Ludwigshafen, Germany. schwarak@klilu.de
Arne Kristian
AK
Schwarz
Uwe
U
Zeymer
D015906:Angioplasty, Balloon, Coronary; D004562:Electrocardiography; D017984:Enoxaparin / Q000627:therapeutic use*; D005343:Fibrinolytic Agents / Q000627:therapeutic use*; D006801:Humans; D009203:Myocardial Infarction / Q000188:drug therapy* / Q000628:therapy
D017984:Enoxaparin; D005343:Fibrinolytic Agents